ERBB2 and breast carcinoma: More recently, Xie et al. [197] validated the newly developed dPCR detection on HER2 status of cfDNA in stage III/IV breast cancer by comparing with tissue biopsy by using immunohistochemistry (IHC)/fluorescence in situ hybridization (FISH).